ClinicalTrials.gg
RecruitingNCT06892379Updated Nov 19, 2026

A Study of HS-20110 in Participants With Advanced Solid Tumors

A Phase 1 interventional study of HS-20110 and HS-20110 in Solid Tumors, sponsored by Hansoh BioMedical R&D Company. Recruiting at 9 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Hansoh BioMedical R&D Company (part of Hansoh Pharmaceutical Group Company Limited) · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 8 months later.
Updated Nov 19, 2026Study completion movedEnrollment updated+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
631
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is an open-label, multicenter study to evaluate the safety and tolerability of HS-20110 in participants with advanced solid malignant tumors

02

Conditions studied

  • Solid Tumors
03

In context

Lead sponsor

Hansoh BioMedical R&D Company is the lead sponsor of 48 studies on the registry; 43 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Nov 19, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males or females, aged ≥ 18 years.
  2. Participants with pathologically (histologically or cytologically) confirmed advanced solid tumors.
  3. Participants have at least 1 target lesion other than CNS lesions according to 1.1 and not intended to be biopsied.

Exclusion criteria

Exclusion Criteria:

  1. Participants have received or are receiving the following treatment:

    1. Previous or concurrent treatment with any CDH17-targeting therapy, including small molecules, monoclonal antibodies, bispecific antibodies, antibody-drug conjugates (ADCs), or CAR-T cell therapy.
    2. Cytotoxic chemotherapy, traditional Chinese medicine with anti-tumor indications, or other anti-tumor drugs within 14 days before the first dose; or other medicinal products (IMPs) or macromolecular anti-tumor drugs (e.g., monoclonal antibodies, ADCs, or bispecific antibodies) within 28 days before the first dose. Continued treatment with these drugs during the study is also not permitted.
    3. Local radiotherapy within 2 weeks before the first dose, or radiotherapy involving >30% of the bone marrow or extensive radiotherapy within 4 weeks before the first dose.
    4. Major surgery within 4 weeks before the first dose.
    5. Use of moderate-to-strong inhibitors or inducers, or strong inhibitors of CYP2D6, P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), organic anion transporting polypeptide 1B1 (OATP1B1), or OATP1B3 within 7 days before the first dose, or requiring these medications during the study.
    6. Current use of medications known to prolong the or cause torsade de pointes, or anticipated use of such medications during the study.
    7. Receipt of live or within 28 weeks before the first dose.
  2. Participants who have any persistent treatment-related toxicity of Grade ≥2 according to the National Cancer Institute (NCI CTCAE) v5.0, except for alopecia and residual neurotoxicity.
  3. Inadequate bone marrow, hepatic, or renal function.
  4. Participants with a history of severe allergic reactions, severe infusion-related reactions, or known allergy to recombinant human or murine proteins.
  5. Participants who has known allergy or to any component of HS-20110.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
631 participants (estimated)

Study arms

  • Experimental
    HS-20110 (Phase Ia:Dose escalation )

    Drug: HS-20110

  • Experimental
    HS-20110 Monotherapy (Phase Ib: Cohort 1a, China Only)

    Drug: HS-20110

  • Experimental
    HS-20110 Combination Therapy (Phase Ib: Cohort 1b, Part 1 - Dose Escalation, ex-China Only)

    Drug: HS-20110 in combination with bevacizumab, 5-fluorouracil (5-FU), and leucovorin.

  • Experimental
    HS-20110 Combination Therapy (Phase Ib: Cohort 1b, Part 2 - Dose Optimization, ex-China Only)

    Drug: HS-20110 in combination with bevacizumab, 5-FU, and leucovorin.

  • Experimental
    HS-20110 Monotherapy (Phase Ib: Cohort 2)

    Drug: HS-20110

  • Experimental
    HS-20110 Monotherapy (Phase Ib: Cohort 3, China Only)

    Drug: HS-20110

Interventions

  • DrugHS-20110

    HS-20110 will be administered by intravenous infusion in 21 day or 28 day dosing cycles.

  • DrugHS-20110

    The recommended dose from the dose-escalation stage and other potential doses will be further explored. HS-20110 for will be administered by intravenous infusion at selected dose levels, administered in 21 day or 28 day dosing cycles.

  • DrugHS-20110 in combination with bevacizumab, 5-fluorouracil (5-FU), and leucovorin.

    HS-20110 will be administered by intravenous infusion on a Q2W schedule at the dose level determined by the SRC in combination with the standard-of-care regimen in 28 days dosing cycles.

  • DrugHS-20110 in combination with bevacizumab, 5-FU, and leucovorin.

    HS-20110 will be administered by intravenous infusion at selected dose levels and schedules in combination with the standard-of-care regimen.

06

What researchers measure

Primary outcomes

  1. Maximum tolerated dose (MTD) or maximum applicable dose (MAD)

    Time frame: From day 1 to one months after the last dose in Phase 1a

  2. Objective response rate (ORR) as per RECIST v1.1

    Time frame: From screening to 2 months after the last dose

Secondary outcomes

  1. Incidence of adverse events (AEs), serious adverse events (SAEs), AEs leading to dose modification or permanent discontinuation, and specific laboratory abnormalities

    Time frame: From the first dose until 90 days after the last dose

  2. Objective response rate (ORR), disease control rate (DCR), duration of response (DoR), and progression-free survival (PFS) as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1; overall survival (OS)

    Time frame: From screening to up to 3 years after last dose

  3. Incidence of anti-HS-20110 antibody (ADA)

    Time frame: From the first dose until 90 days after the last dose

  4. Drug concentrations of the three components of HS-20110 (including antibody-drug conjugates, total antibody, and payload)

    Time frame: From the first dose until 90 days after the last dose

07

Study locations

9 of 9 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Feb 2025 (actual). Primary completion is estimated for Dec 2026, 22 months after the start.

Completion moved once since we started tracking on Sep 25, 2026: Sep 2027 → Mar 2029, on Nov 19, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 24, 2025
First posted
Mar 24, 2025
StartActual
Feb 26, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Mar 3, 2029was Sep 2027
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added
Show site
  • Winship Cancer Institute · Atlanta, United States
Nov 19, 2026
Study completion
Sep 30, 2027→Mar 3, 2029
Nov 19, 2026
Enrollment
475→631
Nov 19, 2026
Eligibility
1 inclusion criterion edited; 11 exclusion criteria edited
What changed in the criteria
Inclusion criteria
  • EditedParticipants have at least 1 target lesion other than CNS lesions according to RECIST 1.1 and not intended to be biopsied.
Exclusion criteria
  • EditedDrugPrevious or concurrent treatment with any CDH17-targeting therapy targeting CDH17 (such as, including small molecule targeted drugsmolecules, monoclonal antibodies, bispecific antibodies, antibody-drug conjugates (ADCs), or chimeric antigen receptor CAR-T cells)cell therapy.
  • ChangedBefore Anti-tumor drugs within 14 days prior to the first dose of study treatment; any other IMPs or macromolecular anti-tumor drugs within 28 days prior to the first dose of study treatment.Now Cytotoxic chemotherapy, traditional Chinese medicine with anti-tumor indications, or other anti-tumor drugs within 14 days before the first dose; or other investigational medicinal products (IMPs) or macromolecular anti-tumor drugs (e.g., monoclonal antibodies, ADCs, or bispecific antibodies) within 28 days before the first dose. Continued treatment with these drugs during the study is also not permitted.
  • EditedLocal radiotherapy within 2 weeks prior tobefore the first dose of study treatment; irradiation of more than , or radiotherapy involving >30% of the bone marrow or extensive radiotherapy within 4 weeks prior tobefore the first dose of study treatment.
  • EditedMajor surgery within 4 weeks prior tobefore the first dose of study treatment.
  • ChangedBefore Participants previously treated with drugs that are moderate to strong inhibitors or moderate to strong inducers of cytochrome P450 (CYP) 3A4, strong inhibitors or strong inducers of CYP2D6, P-glycoprotein (P-gp), breast cancer resistance protein (BCRP) or drugs with a narrow therapeutic range that are sensitive substrates of P-gp or BCRP within 7 days prior to the first dose of the IMP. Participants who need to receive these drugs during the study period should also be excluded.Now Use of moderate-to-strong CYP3A4 inhibitors or inducers, or strong inhibitors of CYP2D6, P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), organic anion transporting polypeptide 1B1 (OATP1B1), or OATP1B3 within 7 days before the first dose, or requiring these medications during the study.
  • EditedCurrent use of drugsmedications known to prolong the QT interval or that may cause torsade de pointes. Participants who need to receive these drugs, or anticipated use of such medications during the study period should also be excluded.
  • EditedLive vaccineReceipt of live or live-attenuated vaccinevaccines within 28 weeks prior tobefore the first dose.
  • EditedParticipants who have any persistent treatment-related toxicity of Grade ≥ 2 residual toxicity according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0, version 5.0) from prior therapies (exceptexcept for alopecia and residual neurotoxicity).
  • EditedInadequate bone marrow reserve, hepatic, or hepatic and renal functionsfunction.
  • EditedParticipants with a history of severe allergy (such as anaphylactic shock)allergic reactions, previous severe infusion-related reactions, or known allergy to recombinant human or murine proteins.
  • EditedParticipants who are allergichas known allergy or hypersensitivity to any component of HS-20110.
Nov 19, 2026
Interventions
Changed HS-20110 (Phase Ia:Dose escalation )→HS-20110; HS-20110 (Phase Ib:Dose expansion )→HS-20110. Added Drug: HS-20110 in combination with bevacizumab, 5-fluorouracil (5-FU), and leucovorin.·Drug: HS-20110 in combination with bevacizumab, 5-FU, and leucovorin.. Arm changed HS-20110 (Phase 1b Dose expansion)→HS-20110 Monotherapy (Phase Ib: Cohort 2). Arms added: HS-20110 Monotherapy (Phase Ib: Cohort 1a, China Only)·HS-20110 Combination Therapy (Phase Ib: Cohort 1b, Part 1 - Dose Escalation, ex-China Only)·HS-20110 Combination Therapy (Phase Ib: Cohort 1b, Part 2 - Dose Optimization, ex-China Only)·HS-20110 Monotherapy (Phase Ib: Cohort 3, China Only)
Nov 19, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • BRCR Medical Center INC · Tamarac, United StatesContact person changed (no phone or email listed)
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    1 site added
    Show site
    • Winship Cancer Institute · Atlanta, United States
    Study completion Sep 30, 2027→Mar 3, 2029
    Enrollment 475→631
    Eligibility 1 inclusion criterion edited; 11 exclusion criteria edited
    What changed in the criteria
    Inclusion criteria
    • EditedParticipants have at least 1 target lesion other than CNS lesions according to RECIST 1.1 and not intended to be biopsied.
    Exclusion criteria
    • EditedDrugPrevious or concurrent treatment with any CDH17-targeting therapy targeting CDH17 (such as, including small molecule targeted drugsmolecules, monoclonal antibodies, bispecific antibodies, antibody-drug conjugates (ADCs), or chimeric antigen receptor CAR-T cells)cell therapy.
    • ChangedBefore Anti-tumor drugs within 14 days prior to the first dose of study treatment; any other IMPs or macromolecular anti-tumor drugs within 28 days prior to the first dose of study treatment.Now Cytotoxic chemotherapy, traditional Chinese medicine with anti-tumor indications, or other anti-tumor drugs within 14 days before the first dose; or other investigational medicinal products (IMPs) or macromolecular anti-tumor drugs (e.g., monoclonal antibodies, ADCs, or bispecific antibodies) within 28 days before the first dose. Continued treatment with these drugs during the study is also not permitted.
    • EditedLocal radiotherapy within 2 weeks prior tobefore the first dose of study treatment; irradiation of more than , or radiotherapy involving >30% of the bone marrow or extensive radiotherapy within 4 weeks prior tobefore the first dose of study treatment.
    • EditedMajor surgery within 4 weeks prior tobefore the first dose of study treatment.
    • ChangedBefore Participants previously treated with drugs that are moderate to strong inhibitors or moderate to strong inducers of cytochrome P450 (CYP) 3A4, strong inhibitors or strong inducers of CYP2D6, P-glycoprotein (P-gp), breast cancer resistance protein (BCRP) or drugs with a narrow therapeutic range that are sensitive substrates of P-gp or BCRP within 7 days prior to the first dose of the IMP. Participants who need to receive these drugs during the study period should also be excluded.Now Use of moderate-to-strong CYP3A4 inhibitors or inducers, or strong inhibitors of CYP2D6, P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), organic anion transporting polypeptide 1B1 (OATP1B1), or OATP1B3 within 7 days before the first dose, or requiring these medications during the study.
    • EditedCurrent use of drugsmedications known to prolong the QT interval or that may cause torsade de pointes. Participants who need to receive these drugs, or anticipated use of such medications during the study period should also be excluded.
    • EditedLive vaccineReceipt of live or live-attenuated vaccinevaccines within 28 weeks prior tobefore the first dose.
    • EditedParticipants who have any persistent treatment-related toxicity of Grade ≥ 2 residual toxicity according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0, version 5.0) from prior therapies (exceptexcept for alopecia and residual neurotoxicity).
    • EditedInadequate bone marrow reserve, hepatic, or hepatic and renal functionsfunction.
    • EditedParticipants with a history of severe allergy (such as anaphylactic shock)allergic reactions, previous severe infusion-related reactions, or known allergy to recombinant human or murine proteins.
    • EditedParticipants who are allergichas known allergy or hypersensitivity to any component of HS-20110.
    Interventions Changed HS-20110 (Phase Ia:Dose escalation )→HS-20110; HS-20110 (Phase Ib:Dose expansion )→HS-20110. Added Drug: HS-20110 in combination with bevacizumab, 5-fluorouracil (5-FU), and leucovorin.·Drug: HS-20110 in combination with bevacizumab, 5-FU, and leucovorin.. Arm changed HS-20110 (Phase 1b Dose expansion)→HS-20110 Monotherapy (Phase Ib: Cohort 2). Arms added: HS-20110 Monotherapy (Phase Ib: Cohort 1a, China Only)·HS-20110 Combination Therapy (Phase Ib: Cohort 1b, Part 1 - Dose Escalation, ex-China Only)·HS-20110 Combination Therapy (Phase Ib: Cohort 1b, Part 2 - Dose Optimization, ex-China Only)·HS-20110 Monotherapy (Phase Ib: Cohort 3, China Only)
    Site contacts Changed at 1 site. See the sites
    Show the site
    • BRCR Medical Center INC · Tamarac, United StatesContact person changed (no phone or email listed)
    + 1 other change: index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06892379
Collaborators
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Mar 24, 2025
Start date
Feb 26, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Mar 3, 2029 (estimated)
Last update
Nov 19, 2026

Study contacts

Hongyan Wang
Contact
wanghy10@hspharm.com
15111915273
Amanda Guo
Contact
guoj9@hspharm.com

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion